Clinical Trials Logo
  1. Home
  2. Leprosy
  3. NCT03807362

CC-11050 Trial in Nepalese Patients With Erythema Nodosum Leprosum

Leprosy Clinical Trial

Official title:
A Single Center, Open Label Pilot Study to Evaluate the Safety and Efficacy of CC-11050 in Nepalese Patients With Erythema Nodosum Leprosum

Clinical Trial Summary

This study will be a single center, Phase 2, open-label trial to evaluate the safety and efficacy of 200mg CC-11050 administered twice daily taken with food for patients with moderate to severe ENL. The study will be performed in two steps: 1) to evaluate immediate effect in safety and efficacy of drug in 10 males with new or new recurrent episode ENL and, if found to be safe and effective by the DSMB and 2) if allowed by the DSMB, and approved by relevant study stakeholders, an additional 40 ENL patients will be enrolled for up to 52 weeks of treatment. A safety analysis will be conducted on all patients who have received at least one dose of study drug, and will include the frequency of all adverse events and laboratory abnormalities as well as frequency of dose interruptions, dose reductions and treatment discontinuation.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03807362
Study type Interventional
Source The Leprosy Mission Nepal
Contact Mahesh Shah, MD
Phone +9779841203417
Email drmahesh_shah@yahoo.com
Status Recruiting
Phase Phase 2
Start date January 7, 2018
Completion date December 31, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT03302897 - Phase 1 LEP-F1 + GLA-SE Vaccine Trial in Healthy Adult Volunteers Phase 1
Recruiting NCT05243654 - Efficacy and Tolerability of Adjunct Metformin for Multibacillary Leprosy Phase 2
Completed NCT05091216 - The Effects of Traditional Chinese Medicine Mouthwash Solutions on the Oral Health of Leprosy Patients N/A
Completed NCT00860717 - The Use of Low Level Laser Therapy for Wound Healing in Leprosy Patients N/A
Recruiting NCT06222372 - Novel Interventions and Diagnostic Tests for Leprosy N/A
Terminated NCT03084614 - CD8 Reactivity to Microorganisms in Blood and Breast Milk
Recruiting NCT05597280 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy Phase 3
Terminated NCT01751503 - Extramembranous and Interosseous Technique of Tibialis Posterior Tendon Transfer N/A
Active, not recruiting NCT03324035 - Treatment of Neuropathic Pain in Leprosy Phase 3
Completed NCT03683745 - Integrated Mapping of Skin-presenting Neglected Tropical Diseases in Liberia
Recruiting NCT02550080 - Clinical Utility Of Genetic Screening For HLA-B*1301, On Susceptibility To Dapsone Hypersensitivity Syndrome Phase 4
Completed NCT02484469 - Impact of the Virtual Human Project on Team-based Learning: A Randomized-controlled Trial N/A
Completed NCT01165840 - Effect of Weight and/or Obesity on Dapsone Drug Concentrations Phase 4
Completed NCT00919542 - Ciclosporin in the Management of New Erythema Nodosum Leprosum Phase 2
Completed NCT05406479 - Bedaquiline Enhanced Post ExpOsure Prophylaxis for Leprosy (Phase 2) Phase 2
Completed NCT01006759 - Prevention of Disability: Proposal for a Guidance Manual for Leprosy Patients Phase 1
Completed NCT03662022 - Post ExpOsure Prophylaxis for LEprosy in the Comoros and Madagascar Phase 3
Completed NCT01920750 - Leprosy Skin Test Antigens Phase 1 Phase 1
Recruiting NCT06416033 - Serum Irisin Level In Leprosy Patients
Not yet recruiting NCT03947437 - Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients Phase 1/Phase 2